Background: Myelosuppression-related infections remain important causes of morbidity and mortality in children with acute lymphoblastic leukemia (ALL). Methods: By analyzing fecal samples collected at diagnosis and after each of the initial 3 phases of chemotherapy, we evaluated the role of gut microbiota in predicting infections in 199 children with newly diagnosed ALL. The bacterial 16S rRNA gene was analyzed by high-depth sequencing to determine the diversity and composition of the microbiome. Results: After the induction and reinduction I phases of chemotherapy, microbial diversity decreased significantly relative to the prechemotherapy value. After chemotherapy, the relative abundance of certain bacterial taxa (eg, Bacteroidetes) decreased significantly, whereas that of other taxa (eg, Clostridiaceae and Streptococcaceae) increased. A baseline gut microbiome characterized by Proteobacteria predicted febrile neutropenia. Adjusting for the chemotherapy phase and ALL risk level, Enterococcaceae dominance (relative abundance ≥30%) predicted significantly greater risk of subsequent febrile neutropenia and diarrheal illness, whereas Streptococcaceae dominance predicted significantly greater risk of subsequent diarrheal illness. Conclusions: In children undergoing therapy for newly diagnosed ALL, the relative abundance of Proteobacteria before chemotherapy initiation predicts development of febrile neutropenia, and domination of the gut microbiota by Enterococcaceae or Streptococcaceae at any time during chemotherapy predicts infection in subsequent phases of chemotherapy. Clinical Trial Registration: NCT00549848.
Background: Myelosuppression-related infections remain important causes of morbidity and mortality in children with acute lymphoblastic leukemia (ALL). Methods: By analyzing fecal samples collected at diagnosis and after each of the initial 3 phases of chemotherapy, we evaluated the role of gut microbiota in predicting infections in 199 children with newly diagnosed ALL. The bacterial 16S rRNA gene was analyzed by high-depth sequencing to determine the diversity and composition of the microbiome. Results: After the induction and reinduction I phases of chemotherapy, microbial diversity decreased significantly relative to the prechemotherapy value. After chemotherapy, the relative abundance of certain bacterial taxa (eg, Bacteroidetes) decreased significantly, whereas that of other taxa (eg, Clostridiaceae and Streptococcaceae) increased. A baseline gut microbiome characterized by Proteobacteria predicted febrile neutropenia. Adjusting for the chemotherapy phase and ALL risk level, Enterococcaceae dominance (relative abundance ≥30%) predicted significantly greater risk of subsequent febrile neutropenia and diarrheal illness, whereas Streptococcaceae dominance predicted significantly greater risk of subsequent diarrheal illness. Conclusions: In children undergoing therapy for newly diagnosed ALL, the relative abundance of Proteobacteria before chemotherapy initiation predicts development of febrile neutropenia, and domination of the gut microbiota by Enterococcaceae or Streptococcaceae at any time during chemotherapy predicts infection in subsequent phases of chemotherapy. Clinical Trial Registration: NCT00549848.
Authors: T Z DeSantis; P Hugenholtz; N Larsen; M Rojas; E L Brodie; K Keller; T Huber; D Dalevi; P Hu; G L Andersen Journal: Appl Environ Microbiol Date: 2006-07 Impact factor: 4.792
Authors: Ying Taur; Robert R Jenq; Carles Ubeda; Marcel van den Brink; Eric G Pamer Journal: Best Pract Res Clin Haematol Date: 2015-10-22 Impact factor: 3.020
Authors: Jessica R Galloway-Peña; Daniel P Smith; Pranoti Sahasrabhojane; Nadim J Ajami; W Duncan Wadsworth; Naval G Daver; Roy F Chemaly; Lisa Marsh; Shashank S Ghantoji; Naveen Pemmaraju; Guillermo Garcia-Manero; Katayoun Rezvani; Amin M Alousi; Jennifer A Wargo; Elizabeth J Shpall; Phillip A Futreal; Michele Guindani; Joseph F Petrosino; Dimitrios P Kontoyiannis; Samuel A Shelburne Journal: Cancer Date: 2016-05-03 Impact factor: 6.860
Authors: Dionysios A Antonopoulos; Susan M Huse; Hilary G Morrison; Thomas M Schmidt; Mitchell L Sogin; Vincent B Young Journal: Infect Immun Date: 2009-03-23 Impact factor: 3.441
Authors: Charlie G Buffie; Vanni Bucci; Richard R Stein; Peter T McKenney; Lilan Ling; Asia Gobourne; Daniel No; Hui Liu; Melissa Kinnebrew; Agnes Viale; Eric Littmann; Marcel R M van den Brink; Robert R Jenq; Ying Taur; Chris Sander; Justin R Cross; Nora C Toussaint; Joao B Xavier; Eric G Pamer Journal: Nature Date: 2014-10-22 Impact factor: 49.962
Authors: Emmanuel Montassier; Gabriel A Al-Ghalith; Tonya Ward; Stephane Corvec; Thomas Gastinne; Gilles Potel; Phillipe Moreau; Marie France de la Cochetiere; Eric Batard; Dan Knights Journal: Genome Med Date: 2016-04-28 Impact factor: 11.117
Authors: Ronay Thomas; Wendy S W Wong; Reem Saadon; Thierry Vilboux; John Deeken; John Niederhuber; Suchitra K Hourigan; Elizabeth Yang Journal: Pediatr Hematol Oncol Date: 2020-05-19 Impact factor: 1.969
Authors: Jessica R Galloway-Peña; Yushu Shi; Christine B Peterson; Pranoti Sahasrabhojane; Vancheswaran Gopalakrishnan; Chelcy E Brumlow; Naval G Daver; Mansour Alfayez; Prajwal C Boddu; Md Abdul Wadud Khan; Jennifer A Wargo; Kim-Anh Do; Robert R Jenq; Dimitrios P Kontoyiannis; Samuel A Shelburne Journal: Clin Infect Dis Date: 2020-06-24 Impact factor: 9.079
Authors: Teppei Shimasaki; Anna Seekatz; Christine Bassis; Yoona Rhee; Rachel D Yelin; Louis Fogg; Thelma Dangana; Enrique Cornejo Cisneros; Robert A Weinstein; Koh Okamoto; Karen Lolans; Michael Schoeny; Michael Y Lin; Nicholas M Moore; Vincent B Young; Mary K Hayden Journal: Clin Infect Dis Date: 2019-05-30 Impact factor: 9.079
Authors: Samuel L Aitken; Pranoti V Sahasrabhojane; Dimitrios P Kontoyiannis; Tor C Savidge; Cesar A Arias; Nadim J Ajami; Samuel A Shelburne; Jessica R Galloway-Peña Journal: Clin Infect Dis Date: 2021-05-04 Impact factor: 9.079
Authors: Tessa M Andermann; Farnaz Fouladi; Fiona B Tamburini; Bita Sahaf; Ekaterina Tkachenko; Courtney Greene; Matthew T Buckley; Erin F Brooks; Haley Hedlin; Sally Arai; Crystal L Mackall; David Miklos; Robert S Negrin; Anthony A Fodor; Andrew R Rezvani; Ami S Bhatt Journal: Transplant Cell Ther Date: 2021-07-16